Latest Innovation News

Etherstack’s subsidiary Auria Wireless has landed a A$0.8 million contract to upgrade Energy Queensland’s statewide digital radio network, continuing a partnership that dates back over a decade.

Assetora Limited has locked in a $3 million private placement from CloudTech Group, aiming to strengthen its balance sheet and fuel expansion plans. The deal unfolds in two tranches, with key conditions tied to audited reports and ASX reinstatement.

VBX Limited reports promising low-silica bauxite discoveries at East Kalumburu A near its flagship Wuudagu project, alongside key strategic appointments and ongoing drilling programs advancing the project towards a targeted DFS completion in early 2026.

DUG Technology has secured its first purchase order under a major multi-year deal with PETRONAS, nearly doubling the contract’s total value to over US$43 million. This milestone signals a significant ramp-up in DUG’s cloud-based geoscience services.

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

Metallium Limited and Ucore Rare Metals have entered a binding 12-month collaboration to integrate their cutting-edge technologies, aiming to establish the first fully U.S.-based rare earth element refining pathway and reduce reliance on Chinese supply chains.

Peak Rare Earths has dismissed a $240 million acquisition proposal from General Innovation Capital Partners, reaffirming its commitment to Shenghe Resources’ $195 million scheme. The board cites concerns over GICP’s incomplete offer and regulatory uncertainties.

First Graphene’s UK partner Vector Group has filed patents for novel fire-resistant materials enhanced with PureGRAPH graphene, showing 100% self-extinguishing performance and improved safety for construction.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Jatcorp has officially appointed Dr Xinpeng (Sean) Li as its CEO, locking in a three-year contract that underscores a strategic focus on sustainable growth and innovation.

Alterity Therapeutics has unveiled encouraging Phase 2 trial results for ATH434, demonstrating its potential to slow disease progression in Multiple System Atrophy while maintaining a strong safety profile.

Spacetalk Ltd has raised $4.05 million through a combination of a conditional placement and convertible notes to accelerate its geographic expansion and app development, alongside appointing a seasoned director to its board.